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Abstract  23 
Ischemia-induced angiogenesis is critical for tissue repair, but aberrant neovascularization in the 24 
retina causes severe sight impairment. Nitric oxide (NO) has been implicated in neovascular 25 
eye disease because of its pro-angiogenic properties in the retina. Nitric oxide production is 26 
inhibited endogenously by asymmetric dimethylarginines (ADMA and L-NMMA) which are 27 
metabolized by dimethylarginine dimethylaminohydrolase (DDAH) 1 and 2. The aim of this study 28 
was to determine the roles of DDAH1, DDAH2, ADMA and L-NMMA in retinal ischemia-induced 29 
angiogenesis. First, DDAH1, DDAH2, ADMA and L-NMMA levels were determined in adult 30 
C57BL/6J mice. The results obtained revealed that DDAH1 was twofold increased in the retina 31 
compared to the brain and the choroid. DDAH2 expression was approximately 150 fold greater 32 
in retinal and 70 fold greater in choroidal tissue compared to brain tissue suggesting an 33 
important tissue-specific role for DDAH2 in the retina and choroid. ADMA and L-NMMA levels 34 
were similar in the retina and choroid under physiological conditions. Next, characterization of 35 
DDAH1+/- and DDAH2-/- deficient mice by in vivo fluorescein angiography, 36 
immunohistochemistry and electroretinography revealed normal neurovascular function 37 
compared with wildtype control mice. Finally, DDAH1+/- and DDAH2-/- deficient mice were 38 
studied in the oxygen-induced retinopathy (OIR) model, a model used to emulate retinal 39 
ischemia and neovascularization, and VEGF and ADMA levels were quantified by ELISA and 40 
liquid chromatography tandem mass spectrometry. In the OIR model, DDAH1+/- exhibited a 41 
similar phenotyp compared to wildtype controls. DDAH2 deficiency, in contrast, resulted in 42 
elevated retinal ADMA which was associated with attenuated aberrant angiogenesis and 43 
improved vascular regeneration in a VEGF independent manner. Taken together this study 44 
suggests, that in retinal ischemia, DDAH2 deficiency elevates ADMA, promotes vascular 45 
regeneration and protects against aberrant angiogenesis. Therapeutic inhibition of DDAH2 may 46 
therefore offer a potential therapeutic strategy to protect sight by promoting retinal vascular 47 
regeneration and preventing pathological angiogenesis. 48 
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1. Introduction 51 
Adaptive tissue responses to ischemia promote blood flow and angiogenesis that are critical for 52 
normal development, tissue repair and regeneration. In the mature retina, however, ischemia-53 
induced angiogenesis is typically misdirected into the vitreous gel where it not only fails to 54 
redress retinal ischemia but also exacerbates impairment of sight with haemorrhage into the 55 
vitreous gel and tractional retinal detachment (Foster and Resnikoff, 2005). Pathological 56 
angiogenesis is the result of a complex interplay of molecular mediators, cellular interactions 57 
and extracellular matrix modulation, and is the target of novel therapeutic approaches (for a 58 
review see (de Oliveira Dias et al., 2011)). Local therapeutic inhibition of vascular endothelial 59 
growth factor (VEGF) attenuates pathological neovascularization (Avery et al., 2006) but this 60 
strategy fails to promote effective revascularization of ischemic retina. 61 
The ubiquitous biological messenger nitric oxide (NO) promotes vascular dilatation by cGMP-62 
induced smooth muscle relaxation (Archer et al., 1994). In the eye, NO promotes angiogenesis 63 
in experimental models of pathological neovascularization (Ando et al., 2002) and is elevated in 64 
the vitreous of human subjects with proliferative diabetic retinopathy (Hernandez et al., 2002). 65 
NO synthesis from L-arginine is catalyzed by 3 isoforms of nitric oxide synthase (NOS) with 66 
distinct tissue distributions: endothelial NOS (eNOS), neuronal NOS (nNOS) and inducible NOS 67 
(iNOS). Asymmetric dimethylarginine (ADMA) and other asymmetrically methylated arginine 68 
analogs (L-NMMA) are key regulators of NO synthesis as they competitively inhibit the binding 69 
of L-arginine for the active site of NOS (Vallance et al., 1992). Asymmetric methyl-arginines are 70 
endogenously produced on degradation of proteins containing asymmetrically methylated L-71 
arginine residues, and are metabolized to citrulline and dimethylamine by dimethylarginine 72 
dimethylaminohydrolases-1 (DDAH1) and -2 (DDAH2) (Fig. 1) (Leiper et al., 1999)(Ogawa et 73 
al., 1987). These two DDAH isoforms have distinct tissue distributions (Leiper et al., 1999) 74 
suggesting isoform-specific regulation of NOS. DDAH1 is predominantly found in tissues that 75 
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express nNOS whereas DDAH2 is found in high levels in tissues expressing eNOS, which has a 76 
role in promoting angiogenesis in the retina (Fukumura et al., 2001)(Brooks et al., 2001). 77 
Here we show that in retinal ischemia, DDAH2 deficiency elevates ADMA, promotes retinal 78 
vascular regeneration and protects against aberrant neovascularization. 79 
2. Material and Methods 80 
2.1 Generation and identification of DDAH knockout mice:  81 
DDAH1+/- knockout mice were generated as previously described (Leiper et al., 2007). Since 82 
global homozygous deletion of DDAH1 is lethal in utero all experiments were performed on 83 
DDAH1+/- mice (Leiper et al., 2007). Heterozygous DDAH2+/- genetic knockout mice were 84 
obtained from the Texas Institute for Genomic Medicine (http://www.tigm.org/) and bred to 85 
generate homozygous DDAH2-/-, heterozygous DDAH2+/- and wildtype DDAH2+/+ mice. All 86 
animals were managed in accordance with the guidelines of the Association for Research in 87 
Vision and Ophthalmology. In all experiments, weight-matched wildtype littermates were 88 
compared to circumvent inter-litter variability.  89 
2.2 Oxygen-induced retinopathy mouse model (OIR): Nursing dams and their pups were 90 
kept at 75 ±3% O2 in an oxygen supply chamber from postnatal day (p) 7 to p12, returned to 91 
room air on p12 and culled at p12 or p17 as described elsewhere (Lange et al., 2009). The area 92 
of ischemia and neovascularization was studied as previously described (Wang et al., 2013).  93 
2.3 Laser-induced choroidal neovascularization (CNV): Laser-CNV induction and in vivo 94 
fundus fluorescein angiography 7 and 14 days after laser was performed as previously 95 
described (Wang et al., 2013). 96 
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2.4 Electroretinography: Standard photopic and scotopic Ganzfeld ERG’s were recorded 97 
bilaterally in dark-adapted mice using the electrophysiological system Espion 2000 (Espion E2, 98 
Diagnosys LLC, Cambridge, UK) as previously described (Mowat et al., 2012).  99 
2.5 Chemical analysis: Methylarginines were quantified using liquid chromatography tandem 100 
mass spectrometry as previously described (Caplin and Leiper, 2012). VEGF protein levels 101 
were determined using a commercially available ELISA kit (mouse VEGF DuoSet ELISA kit, 102 
R&D, Systems Europe, Abingdon, UK) and were corrected for total protein levels. Western 103 
blotting protein analysis was performed for DDAH1 and DDAH2 in brain, retinal and choroidal 104 
tissue as previously described (Mowat et al., 2010). Mouse beta actin was used as an internal 105 
loading control. Since DDAH and beta actin have similar sizes, beta actin was used after 106 
stripping and reprobing of the blot. Primary antibodies for DDAH1 (1:1000) and 2 (1:2500) were 107 
raised in goats against peptide sequences which are conserved across rats, humans, and mice 108 
as previously described (Wojciak-Stothard et al., 2007).  109 
2.6 Immunohistochemistry: Eyes of anaesthetized animals were fixed by intracardiac 110 
perfusion using 1% paraformaldehyde. Haematoxylin and eosin staining histology and 111 
immunohistochemistry were performed as previously described (Lange et al., 2012). DDAH 112 
immunohistochemistry was performed using polyclonal rabbit anti-DDAH I (1:2000) and 113 
polyclonal rabbit anti-DDAH II antibodies (1:2000, generated in house) as previously described 114 
(Gray et al., 2010). 115 
2.7 Statistical analysis: Data from knockout animals were normalized to littermate controls. 116 
Data were compared using the non-parametric Mann-Whitney U test. Mean variables of more 117 
than two groups were compared by ANOVA with Bonferroni corrections for multiple 118 
comparisons. P-values less than 0.05 were considered statistically significant. 119 
  120 
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3. Results  121 
3.1 Methylarginines and DDAH isoforms are differentially distributed in the murine eye 122 
To investigate the distribution of ADMA, L-NMMA and their catabolizing enzyme DDAH1 and 123 
DDAH2 in the retina and choroid/RPE of normal adult C57BL/6J mice we performed 124 
immunohistochemistry, Western blotting and liquid chromatography tandem mass spectrometry. 125 
Immunohistochemistry revealed that DDAH1 and DDAH2 are expressed in the ganglion cell 126 
layer, the inner nuclear layer and the photoreceptor layer. In addition DDAH2 but not DDAH1 127 
was expressed in the choroidal vasculature (Fig.2A-C). Using Western blot analysis on wildtype 128 
samples we found a twofold increase of DDAH1 expression in the retina compared to the brain 129 
and the choroid. DDAH2 expression in contrast was approximately 150 fold greater in retinal 130 
and 70 fold greater in choroidal tissue compared to brain tissue suggesting an important tissue-131 
specific role for DDAH2 in the retina and choroid (Fig.2D-E). ADMA concentrations were 132 
comparable in both retinal and choroidal tissue. L-NMMA concentration was also similar in the 133 
retina and choroid but at substantially higher concentrations than ADMA (Fig.2F-G).  134 
 135 
3.2 Heterozygous loss of DDAH1 and homozygous loss of DDAH2 are not essential for 136 
neurovascular function 137 
We next explored the role of DDAH1 and DDAH2 in normal retinal development and function 138 
using fluorescein angiography, immunohistochemistry and electroretinography. DDAH1+/-, 139 
DDAH2+/- and DDAH2-/- knockout mice demonstrated a normal vascular phenotype and normal 140 
neuroretinal functioning when compared to littermate controls (Fig.3E-H, S1A-B).  141 
3.3 Loss of DDAH2 reduces pathogenic retinal ischemia and neovascularization  142 
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Having established that heterozygous loss of DDAH1 or homozygous loss of DDAH2 has no 143 
effect on the adult retinal vasculature, we next investigated the role of DDAH1 and DDAH2 in 144 
murine oxygen-induced retinopathy (OIR), a model of retinal ischemia-induced 145 
neovascularization. In OIR, exposure of young mice to hyperoxia (75% inhaled oxygen) from 146 
postnatal day 7 (p7) results in ablation of immature retinal vasculature. On return to room air at 147 
p12 the ischemic retina becomes hypoxic, leading to upregulation of adaptive angiogenic 148 
processes. Neovascularization, however, fails to revascularize ischemic retina appropriately and 149 
instead is misdirected into the vitreous, in a pattern that recapitulates key features of 150 
proliferative diabetic retinopathy. Heterozygous DDAH1 knockout mice demonstrated a similar 151 
oxygen-induced retinal vascular ablation at p12 and a similar area of retinal neovascularisation 152 
at p17 compared with littermate controls (Fig.4G-H). DDAH2+/- knockout mice were similarly 153 
susceptible to oxygen-induced retinal vascular ablation as their littermate (DDAH2+/+) controls. 154 
At p17 however, heterozygous DDAH2+/- knockout mice developed greater revascularization of 155 
the area of retinal vascular ablation, resulting in less extensive ischemia, and less extensive 156 
aberrant pre-retinal neovascularization. Having identified an effect of DDAH2 haploinsufficiency 157 
we then determined that in DDAH2 null (DDAH2-/-) mice the magnitude of this response to OIR 158 
was greater still (Fig.4A-I). These data indicate that dose dependent reduction of DDAH2 159 
promotes appropriate revascularization and reduces aberrant angiogenesis in retinal ischemia.  160 
3.4 DDAH2 deficiency does not alter retinal VEGF levels in the OIR model  161 
Since DDAH2 can induce expression of vascular endothelial growth factor (VEGF), which is well 162 
recognized for its pro-angiogenic role in OIR, we next investigated retinal VEGF protein levels in 163 
DDAH2-deficient mice during OIR. The concentration of VEGF protein was significantly raised in 164 
the retina during the hypoxic phase of OIR. However, the concentration of VEGF was 165 
unaffected by DDAH2 deficiency (Fig. 4J) indicating that the observed attenuated neovascular 166 
response is independent of local VEGF. 167 
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3.5 Retinal ADMA is increased by DDAH2-deficiency in retinal ischemia 168 
Next, we determined the impact of DDAH2 on retinal ADMA and L-NMMA in OIR by liquid 169 
chromatography tandem mass spectrometry. During the hypoxic phase of OIR at p17, retinal 170 
ADMA was significantly increased in DDAH2-/- mice (Fig. 4K) suggesting that increased ADMA 171 
attenuates the development of retinal neovascularization. Although L-NMMA is present in the 172 
normal retina at higher levels than ADMA, we identified no measurable impact of OIR or 173 
DDAH2-deficiency on local L-NMMA (Fig. 4L).  174 
3.6 DDAH2 does not influence pathogenic choroidal neovascularization  175 
To investigate the role of DDAH1 and DDAH2 in angiogenesis in choroidal neovascularization 176 
(CNV), a feature of age-related macular degeneration, we measured the extent of CNV induced 177 
by laser-rupture of Bruch’s membrane in heterozygous DDAH1 and homozygous DDAH2 178 
deficient mice. We identified no significant difference in the extent of CNV in DDAH1+/-, 179 
DDAH2+/- and DDAH2-/- compared with littermate controls (SFig.1&2) suggesting that 180 
heterozygous loss of DDAH1 and loss of DDAH2 do not affect the development of CNV. 181 
4. Discussion 182 
Therapeutic strategies that promote new vessel growth into the ischemic retina and away from 183 
the vitreous body would be extremely beneficial for patients with ischemic retinopathy, such as 184 
proliferative diabetic retinopathy and retinal vein occlusion. In this study we aimed to explore the 185 
role of ADMA and L-NMMA and its catabolizing enzyme DDAH1 and DDAH2, which are potent 186 
regulators of NO synthesis, on vascular regeneration and pathological neovascularization. To 187 
do this we investigated the expression of ADMA and L-NMMA in the ischemic murine retina and 188 
characterized DDAH1 and DDAH2 knockout mice in health and in an established model for 189 
retinal ischemia and neovascularization. 190 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
11 
 
We found that DDAH1 and DDAH2 are expressed to a similar extent in the murine retina while 191 
DDAH2 is the predominant isoform found in the choroid and RPE. Interestingly, DDAH2 192 
expression is approximately 1000fold greater in the retina than in the brain indicating an 193 
important tissue-specific role for DDAH2 in the retina.  194 
To determine the effect of reduced DDAH1 and absent DDAH2 activity on retinal ischemia and 195 
neovascularization we investigated DDAH1+/- and DDAH2-/- deficient mice in two established 196 
models of ocular neovascularisation. We could previously show that DDAH1+/- mice exhibit 197 
reduced DDAH1 protein expression and elevated circulating and tissue ADMA concentrations 198 
(Leiper et al., 2007) which was associated with attenuated hemodynamic consequences in 199 
endotoxemia (Nandi et al., 2012). However, in the OIR and CNV mouse models heterozygous 200 
loss of DDAH1 had no effect on retinal ischemia or the formation of ocular neovascularisation. 201 
This finding is in contrast to the literature which reports on a proangiogenic role of DDAH1. 202 
Overexpression of DDAH1 in transgenic mice is associated with enhanced angiogenesis in a 203 
murine model of hindlimb ischemia (Jacobi et al., 2005) and with augmented endothelial 204 
regeneration after femoral artery injury. (Konishi et al., 2007). Conversly, homozygous loss and 205 
endothelial cell specific knockout of DDAH1 is associated with reduced angiogenesis in vitro 206 
(Zhang et al., 2011)(Hu et al., 2009). Such disparate findings might be explained by the different 207 
mouse models used in the studies and by the omission of homozygous DDAH1-/- deficient mice 208 
from this study as they die in utero (Leiper et al., 2007). Future studies using viable DDAH1-/- or 209 
cell-specific conditional knockout mice are warranted to determine the role of DDAH1 in retinal 210 
ischemia and neovascularisation with greater confidence. 211 
We could recently demonstrate that DDAH2 is an important isoform for ADMA degradation in 212 
myocardial and renal tissue (Lambden et al., 2015). To assess the role of DDAH2 on ADMA 213 
levels, retinal ischemia and neovascularization we investigated DDAH2 deficient mice in health 214 
and in the OIR mouse model. Under normal conditions DDAH2 is predominately expressed in 215 
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the ganglion cell layer, photoreceptor layers and to a lesser extent in the inner nuclear layer. 216 
DDAH2 deficiency caused no abnormality of retinal development or retinal vasculature in adult 217 
mice on fundus imaging, in vivo fluorescein angiography, immunohistochemistry or 218 
electroretinography indicating that DDAH2 does not affect normal neuroretinal development or 219 
function. These findings are consistent with previous reports demonstrating that eNOS knockout 220 
mice exhibit normal retinal vascular development and retinal function (Al-Shabrawey et al., 221 
2003). Under ischemic conditions, however, DDAH2 deficiency was associated with increased 222 
ADMA levels, reduced aberrant angiogenesis and improved vascular regeneration. These data 223 
indicate that DDAH2 deficiency and increased ADMA promotes appropriate revascularization 224 
and reduces aberrant angiogenesis in retinal ischemia most likely via an inhibition of NO 225 
synthase. These data are consistent with previous studies demonstrating that deficiency of 226 
endothelial- or inducible-NOS suppresses retinal neovascularization and improves vascular 227 
repair in the OIR model (Sennlaub et al., 2001)(Brooks et al., 2001). iNOS-deficient mice 228 
develop a substantial reduction of the area of ischemia by about 70% and a reduction of 229 
preretinal neovascularization by about 85% at p17 (Sennlaub et al., 2001). eNOS-deficient mice 230 
exhibit a 46% reduction of the area of retinal ischemia and a reduction of retinal 231 
neovascularisation by about 66% (Brooks et al., 2001) similar to our own findings in DDAH2-232 
deficient mice. In addition to their roles in the regulation of NO production, DDAH enzymes are 233 
also involved in NOS-independent pathways. Since DDAH2 can induce expression of vascular 234 
endothelial growth factor (VEGF) in cultured endothelial cell (Hasegawa et al., 2006), which is 235 
well recognized for its pro-angiogenic role in OIR (Aiello et al., 1995), we investigated retinal 236 
VEGF protein levels in DDAH2-deficient mice during OIR. The concentration of VEGF protein 237 
was significantly raised in the retina during the hypoxic phase of OIR, a finding that is consistent 238 
with previous reports (Pierce et al., 1996). We could recently show that VEGF is expressed in 239 
the ganglion cell layer, the inner nuclear layer and the retinal pigmented epithelium upon OIR 240 
induction (Liyanage et al., 2016). However, the concentration of VEGF was unaffected by 241 
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DDAH2 deficiency indicating that DDAH2 deficiency does not affect VEGF expression in these 242 
cell layers. Taken together the data suggests that locally increased levels of the NOS inhibitor 243 
ADMA promotes retinal vascular regeneration and attenuates aberrant neovascularization 244 
independently of local VEGF concentration. This hypothesis is consistent with previous studies 245 
demonstrating that deficiency of endothelial- or inducible-NOS suppresses retinal 246 
neovascularization and improves vascular regeneration in retinal ischemia independent of 247 
VEGF (Ando et al., 2002)(Brooks et al., 2001)(Sennlaub et al., 2001). 248 
There is ongoing controversy concerning the distribution and functional contribution of DDAH1 249 
and DDAH2 to the degradation of ADMA. Using DDAH1 knockout mice Hu et al convincingly 250 
demonstrated that DDAH1 is responsible for the majority of enzyme activity for metabolizing 251 
ADMA in the kidney, brain, lung and plasma (Hu et al., 2011). Selective DDAH2 gene silencing 252 
by siRNA was shown to have no effect on ADMA content in cultured bovine aortic endothelial 253 
cells or on serum ADMA in unchallenged rats (Wang et al., 2007)(Hu et al., 2011) suggesting 254 
that DDAH2 might not metabolize ADMA in vivo (Pope et al., 2009). These studies on DDAH2, 255 
however, may have been limited by gene silencing efficacy and by the fact that ADMA was 256 
measured in endothelial cells in vitro and in the blood but not in tissues. Using DDAH2 knockout 257 
mice we could recently demonstrate that DDAH2 has an important role in degrading ADMA in 258 
myocardial and renal tissue (Lambden et al., 2015) which is in line with the finding of increased 259 
retinal ADMA in challenged DDAH2 knockout mice, as observed in this study. 260 
Moreover, DDAH2 gene silencing studies indicate that DDAH2 regulates tissue ADMA levels 261 
and NO bioavailabilty in isolated mesenteric resistance vessels (Wang et al., 2007) and human 262 
genetic studies demonstrate that polymorphisms in the DDAH2 gene are associated with altered 263 
plasma ADMA levels (Abhary et al., 2010). Taken together these studies indicate that DDAH2 264 
does indeed contribute to ADMA regulation in particular in highly vascularized tissues such as 265 
the retina. 266 
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 267 
5. Conclusions 268 
In summary, our results indicate that DDAH2 prevents ADMA upregulation in retinal ischemia, 269 
impairing retinal vascular regeneration and promoting aberrant neovascularization. Deficiency of 270 
DDAH2 does not affect normal neuroretinal development or function but, in the context of 271 
ischemia, strongly promotes vascular regeneration and protects against pathological 272 
neovascularization. This mechanism is gene dose-dependent, tissue-selective and independent 273 
of VEGF. Therapeutic intervention to increase ADMA , for example by small molecules inhibition 274 
of DDAH2 (Leiper and Nandi, 2011), may offer the means to promote vascular regeneration and 275 
prevent retinal neovascularization in common conditions associated with retinal ischemia. 276 
 277 
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FIGURES 289 
 290 
Fig. 1: Regulation of Nitric Oxide synthesis by Methylarginines (ADMA and L-NMMA). L-291 
arginine is the substrate for nitric oxide synthase (NOS) enzymes. Arginine residues in proteins 292 
are methylated by protein arginine methyl transferases. Following proteolysis of arginine-293 
methylated proteins, methylarginines (ADMA and L-NMMA) accumulate in the cytosol where 294 
they can inhibit NOS activity by competing with arginine at the NOS active site. Inhibitory 295 
methylarginines are metabolized by the action of dimethylarginine dimethylaminohydrolase 296 
(DDAH1 and DDAH2). 297 
 298 
Fig. 2: DDAH1 and DDAH2 expression in the retina. A-B) DDAH1 and DDAH2 299 
immunohistochemistry in adult C57BL/6J mice. C) No primary antibody control. D-E) DDAH1 300 
and DDAH2 protein levels in the brain, retina and choroid/RPE in adult C57BL/6J mice and 301 
representative Western blots (n= 5 animals per group). F-G) ADMA and L-NMMA concentration 302 
in the retina and choroid/RPE in adult C57BL/6J mice (n= 5 animals per group). GCL= ganglion 303 
cell layer; IPL= inner plexiform layer; INL inner nuclear layer; OPL= outer plexiform layer; ONL = 304 
outer nuclear layer; Cho= choroid; RPE = retinal pigment epithelium. Bars represent mean (± 305 
SEM). 306 
 307 
Fig. 3: DDAH2 deficiency does not alter retinal neurovascular morphology and function. 308 
A) Representative infrared fundus images, (B) fluorescein angiography, (C) vessel-stained 309 
retinal flatmounts and (D) cryosections of control (first column), DDAH2+/- (second column) and 310 
DDAH2-/- littermates (right column) at one month of age (n= 3-4 per group). E) H&E histology 311 
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reveals a normal retinal layering and thickness in control, DDAH2+/- and DDAH2-/- knockout mice 312 
(n= 3-4 per group). F) Representative scotopic electroretinogram recordings and quantification 313 
of the a- and b-wave amplitude at 1 Cds/m2 intensity in adult DDAH1+/-, DDAH2+/- DDAH2-/- and 314 
their representative littermates (n=6 animals per group); GCL= ganglion cell layer; IPL= inner 315 
plexiform layer; INL inner nuclear layer; OPL= outer plexiform layer; ONL = outer nuclear layer; 316 
Cho= choroid; RPE = retinal pigment epithelium. Bars represent mean (± SEM). 317 
 318 
Fig. 4: DDAH2-deficiency increases ADMA levels in retinal ischemia, promotes 319 
revascularization and attenuates aberrant neovascularization. A-F) Representative vessel-320 
stained retinal flatmounts of DDAH2+/+ (control), DDAH2+/- and DDAH2-/- littermates at p12 (A-C) 321 
and p17 (D-F) in oxygen-induced retinopathy (OIR). The ischemic area is outlined in white; the 322 
area of aberrant neovascularization is highlighted in yellow. G-H) Mean area of 323 
neovascularization (G) and ischemic fraction (H) in DDAH1+/- (n=6), DDAH2-/+ (n=21) DDAH2-/- 324 
(n=10) and their representative wildtype littermate controls (n=15, n=6) at P17 after OIR 325 
induction (data is presented as percentage of total retinal area relative to wildtype littermate 326 
controls). I) Timecourse of mean ischemic fraction of total retinal area in DDAH2+/+, DDAH2+/- 327 
and DDAH2-/- littermates at p12 and p17 in oxygen induced retinopathy (range n=5-8 per group). 328 
J-L) Mean retinal VEGF protein (J), ADMA (K) and L-NMMA (L) levels in DDAH2+/+ controls, 329 
DDAH2+/- and DDAH2-/- littermates (range n=5-8 per group) at p17 under normoxic condition and 330 
after OIR induction (data is presented relative to normoxic wildtype littermate controls). Bars 331 
represent mean (± SEM). NV = neovascularization. **** = p<0.0001, *** = p<0.001, ** = p<0.01 332 
(ANOVA with the Bonferroni correction for multiple significance tests).  333 
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Supplementary Fig. 1: Heterozygous loss of DDAH1 does not affect vascular 335 
morphology, permeability or pathological angiogenesis in the laser-induced CNV model. 336 
A, B) Early (90 sec) and late phase (7 min) fluorescein angiography in adult wildtype (left 337 
column) and DDAH1+/- knockout mice (right column, n=5 animals per group) demonstrating no 338 
gross vascular anomalies or permeability defects. C, D) Early fluorescein angiography of laser-339 
induced choroidal neovascularisation in wildtype and DDAH1+/- knockout mice. D) Mean CNV 340 
lesion size at 7 days following laser injury (n= 4-6 animals per group). Bars represent mean (± 341 
SEM). 342 
 343 
Supplementary Fig. 2: DDAH2 does not contribute to laser induced CNV. A-C) Early and 344 
late (‘) fluorescein angiographies of representative CNV lesions of adult DDAH2+/+ (control), 345 
DDAH2+/- and DDAH2-/- littermates 2 weeks after laser CNV induction. D, E: Mean area of CNV 346 
in DDAH2+/+ (control, n=6), Ddah-2+/- (n=7) and DDAH2-/- littermates (n=6) 2 weeks after laser 347 
CNV induction (data is presented relative to wildtype littermate controls). Bars represent mean 348 
(± SEM). 349 
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Highlights: Dimethylarginine dimethylaminohydrolase-2 deficiency promotes  
vascular regeneration and attenuates pathological angiogenesis 
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•
 Nitric oxide has been implicated in neovascular eye disease. 
•
 Key inhibitor of NO production is ADMA, which is metabolized by DDAH. 
•
 DDAH2 deficiency results in elevated ADMA and reduced neovascularisation in mice. 
•
 Therapeutic inhibition of ADMA or DDAH2 may offer a potential therapeutic strategy. 
